ATRA - צמיחת מכירות משנה לשנה (TTM) Atara Bio

Year-over-year sales volume growth over the last 12 months demonstrates the asset's dynamics, where -97.30 becomes the new value for this metric. Atara Biotherapeutics (ATRA) is currently experiencing volatility due to a temporary slowdown in product launches despite possessing strong patent protections. Stability is maintained by diversifying development between oncology and autoimmune pathologies. Revenues are based on the commercialization of transplant complication therapies and future sales of T-cell methods.
Atara Biotherapeutics, Inc. (ATRA) - פילוחי מדדים ודוחות פיננסיים

This indicator measures revenue dynamics, neutralizing short-term volatility through a rolling annual period. By analyzing the annual growth in sales volumes over the trailing four quarters, an investor assesses the sustainability of the business's commercial expansion. The calculation is based on a percentage comparison of the current TTM total revenue against the same figure from the previous year. For Atara Biotherapeutics (ATRA), this reflects market recognition of their innovative T-cell therapy. Growth in this metric confirms the successful implementation of viral pathology treatment methods into oncological practice.